• Street Talk

Alzheimer’s drug developer Actinogen rattles the tin

Actinogen would use the proceeds to expand the Phase 2b trials of its XanaMIA treatment for Alzheimer’s to a full enrolment of 220 patients.

• Sep 17, 2024
• Sarah Thompson, Kanika Sood and Emma Rapaport

• Street Talk

Bell Potter raising for Alzheimer's drug hopeful Actinogen

ASX-listed Actinogen Medical is in front of potential investors seeking a $10 million equity injection to fund a trial for its Alzheimer's drug. 

• Oct 13, 2020
• Sarah Thompson, Anthony Macdonald and Tim Boyd

Actinogen Medical raises $5.2m for Alzheimer's treatment

Alzheimer's disease is the second biggest killer of Australians, but investors have just bet $5.3 million that an ASX-listed company has the cure.

• Dec 6, 2017
• Michael Bailey

• Opinion

In innovation and biotech let's party like it's 1998

Conditions may be bad but in 1997 they were also bad and 1998 was expected to be far worse, but then the sharemarket boomed.

• Updated Jan 4, 2016
• Martin Rogers